A Phase 3 study to evaluate the efficacy and safety of birtamimab plus standard of care compared to placebo plus standard of care in Mayo Stage IV patients with AL amyloidosis.
Light Chain (AL) Amyloidosis
A Phase 3 study to evaluate the efficacy and safety of birtamimab plus standard of care compared to placebo plus standard of care in Mayo Stage IV patients with AL amyloidosis.
A Study to Evaluate the Efficacy and Safety of Birtamimab in Mayo Stage IV Patients with AL Amyloidosis
-
University of California San Francisco, San Francisco, California, United States, 94143
St. Francis Hospital, Hartford, Connecticut, United States, 06105
Yale Cancer Center, North Haven, Connecticut, United States, 06473
Smilow Cancer Hospital Care Center at Trumbull, Trumbull, Connecticut, United States, 06611
MedStar Georgetown University Hospital, Washington, District of Columbia, United States, 20007
Cleveland Clinic Florida, Weston, Florida, United States, 33331
Goshen Center for Cancer Care, Goshen, Indiana, United States, 46526
Johns Hopkins University, Bethesda, Maryland, United States, 20814-1422
Boston University School of Med., Boston, Massachusetts, United States, 02118
Dana-Farber Cancer Institute, Boston, Massachusetts, United States, 02215
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
For general information about clinical research, read Learn About Studies.
18 Years to
ALL
No
Prothena Biosciences Ltd.,
2027-06